{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"41.3","value":"9.1"},{"groupId":"OG001","lowerLimit":"10.9","upperLimit":"69.2","value":"36.4"},{"groupId":"OG002","lowerLimit":"0.2","upperLimit":"41.3","value":"9.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"description":"Percentage of participants with a reduction of mean GH levels to \\< 2.5 µg/L and the normalization of IGF-1 to within normal limits (age and sex related) at 3 months in each starting dose.","dispersionType":"95% Confidence Interval","groups":[{"description":"Enrolled patients were randomized to 20mg pasireotide LAR.","id":"OG000","title":"Pasireotide LAR 20mg"},{"description":"Enrolled patients were randomized to 40mg pasireotide LAR.","id":"OG001","title":"Pasireotide LAR 40mg"},{"description":"Enrolled patients were randomized to 60mg pasireotide LAR.","id":"OG002","title":"Pasireotide LAR 60mg"}],"paramType":"NUMBER","populationDescription":"FAS: Comprises all patients to whom study treatment has been assigned by randomization. According to the intent to treat principle, patients were analyzed according to the study treatment they have been assigned to during the randomization procedure.","reportingStatus":"POSTED","timeFrame":"Month 3","title":"Response Rate at Month 3 by Randomized Dose Level","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}